loteprednol etabonate · Alcon Labs Inc · NDA 210565
Inveltys
Earliest generic entry, as listed
3 May 2033
Blocked by patent: US 10058511, US 10646437, US 10688045, US 10864219, US 11219597, US 11219597, US 11642317, US 11872318, US 12115246, US 9056057, US 9393213, US 9532955, US 9737491, US 9827191.
Listed patents · 14 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10058511 | product, use U-2492 | 3 May 2033 |
| US 10646437 | product | 3 May 2033 |
| US 10688045 | product | 3 May 2033 |
| US 10864219 | use U-3011 | 3 May 2033 |
| US 11219597 | use U-3279 | 3 May 2033 |
| US 11219597 | use U-3278 | 3 May 2033 |
| US 11642317 | product | 3 May 2033 |
| US 11872318 | product | 3 May 2033 |
| US 12115246 | product, use U-4025 | 3 May 2033 |
| US 9056057 | product, use U-2491 | 3 May 2033 |
| US 9393213 | product | 3 May 2033 |
| US 9532955 | use U-2491 | 3 May 2033 |
| US 9737491 | use U-2492 | 3 May 2033 |
| US 9827191 | product, use U-2493 | 3 May 2033 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 210565 · 001 · RLD | suspension/drops, ophthalmic | 1% | 3 May 2033 |